This should be required reading for every fellow! If NETs have ever confused you (they still confuse me), look no further. Great review by @NVijayvergiaMD . @UGrewalMD does this pass the muster of another big NET guy?
Teamed up with #BrysonKatona & #LindaLee to make sense of the ever-confusing world of #NETs in our @AGA_Gastro review—hope it helps every GI and Onc specialist who meets these sneaky tumors on a “routine” scope gastrojournal.org/article/S0016-… @FoxChaseCancer @PennMedicine @BrighamWomens
Excited to share Colorectal Cancer updates from ESMO 2025 with Colontown this Tuesday November 11th at 11:30AM! We'll talk about the practice-changers, the puzzles and the take-aways that can impact patient-care today. Link below: paltown.app.neoncrm.com/np/clients/pal… #CRCSM @OncoAlert…
Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer”…
And another Top 3 #ESMO25 round up spanning GI malignancies from @UGrewalMD !
🤩 #ESMO25 GI oncology highlights from @UGrewalMD! ✅ MATTERHORN: Peri-op durvalumab + FLOT→⬆️OS ✅ CARES-009: Camrelizumab + rivoceranib peri-op HCC → EFS 42.1 vs 19.4 mo ✅ STELLAR-303: Zanzalintinib + atezo beats rego in MSS mCRC 💥Full roundup⬇️: oncupdates.com/article/key-up…
My #OncoAlertAF “TOP3” from #ESMO25… featuring a bold new format: just two. ✅ NICHE-2 ✅ STELLAR-303 Because quality > quantity 😎 @OncoAlert @TheGutOncLab @UGrewalMD @TimothyJBrownMD
Our #OncoAlertAF 🚨Colleague @GIMedOnc 🇺🇸 of @NorthwellHealth with his TOP picks of #GIOncology Trials Presented at #ESMO25 🇩🇪for the OncoAlert TOP3 Series post ESMO 2025, more to come.. ✅NICHE2 ✅STELLAR 303 @pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm…
Feeling Inspired after the @Google Cancer AI Symposium 2025. So many things in the works (and working). It’s an exciting time to be an oncologist!
Absolute honor to be able to count @UGrewalMD as a colleague and a friend.
Incredibly honored to receive this recognition from @NANETS1 for our work on equity in the care of patients with Neuroendocrine Neoplasms. This award will serve as a constant reminder for me to continue on this path to ensure that we make progress equitable and available to all…
Overjoyed to have had the opportunity to host my VERY FIRST podcast! NetCast 🎙️ Thank you @NANETS1 for the opportunity and thanks to wonderful panelists @AmanChauhanMD @SShaheenMD and Dr Iyer. Eagerly looking forward to this episode.
#ESMO25 has passed; now comes the mother of all oncoalert newsletters recapping ALL THE THINGS. Check back on Monday. @OncoAlert
THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨COMES OUT Monday October 27, 2025‼️ TO GET IT REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… 5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪 @matteolambe @christine_lovly @peters_solange @aftimosp…
Holy smokes. Amazed to be in the company of @ArndtVogel and @Erman_Akkus ! Looking forward to keep shining a critical eye towards #GIOnc. Really excited with all the progress that is being made. Thanks @Larvol
@myESMO 2025 Recap: Top GI Cancer Trials and Key Results Explore more insights and data from #ESMO25: t.ly/yDvnj #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #GICancer | @Erman_Akkus | @ArndtVogel |…
10 minutes to go ⏰ Join us LIVE as we break down the biggest #ESMO25 highlights in GI oncology 🎙️ With @TimothyJBrownMD, @UGrewalMD, and @GIMedOnc 👉 x.com/i/spaces/1BRJj… #ESMO25
🎙️ Tune in at 7 PM EST on 10/20, to catch a live discussion on top GI abstracts from #ESMO25 🎙️ @TimothyJBrownMD, @GIMedOnc, and @UGrewalMD will discuss all you need to know to stay up to date! Join here:
ctDNA guidance takes a step, not a leap, in stage III colon cancer 🧬🩸 DYNAMIC-III (LBA9) tested ctDNA-guided adjuvant de-escalation after surgery for stage III colon cancer. 🧪 968 patients → 702 ctDNA– randomized to ctDNA-guided vs standard chemo 💉 Oxaliplatin use: 35% vs…
PARERE puts sequencing to the test in chemorefractory mCRC 🔁🧬 Phase 2 PARERE trial compared panitumumab rechallenge with Regorafenib RAS/BRAF WT ctDNA–selected mCRC. 📊 mOS: 11.6 vs 11.7 months — identical 📈 PFS favored panitumumab in both sequences 🧠 Interpretation:…
NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67%…
CARES-009 raises the bar for resectable HCC 🧬🩸 Phase 3 CARES-009 trial tested perioperative camrelizumab (PD-1) + rivoceranib (VEGFR + PD-1 combo) vs upfront surgery in resectable intermediate/high-risk HCC (CNLC Ib–IIIa). 🧠 Design: 2 cycles neoadjuvant → resection → ≥6…
A Great Day 2 of #ESMO25 Our most sincere thanks to the @myESMO Faculty and Staff for an amazing day of the Congress. ✅87.5 Million Impressions🌐 ✅5.3K Posts Indeed an Amazing meeting in BERLIN🇩🇪 WE ARE ALL OncoAlert🚨 👉Stats Powered by MedTrackSocial.com Free and No…
United States 趨勢
- 1. Good Sunday 58.8K posts
- 2. #UFC322 203K posts
- 3. #LingTaoHeungAnniversary 785K posts
- 4. #GirlPower N/A
- 5. Islam 321K posts
- 6. LING BA TAO HEUNG 786K posts
- 7. #sundayvibes 3,794 posts
- 8. For with God 27.2K posts
- 9. Lingling Kwong 14.9K posts
- 10. Wuhan 14.5K posts
- 11. Morales 40.3K posts
- 12. Ilia 9,477 posts
- 13. Valentina 17.2K posts
- 14. Khabib 17.6K posts
- 15. #MakeOffer 6,117 posts
- 16. Domain For Sale 6,596 posts
- 17. Flip Wilson N/A
- 18. Dagestan 4,844 posts
- 19. Prates 38.9K posts
- 20. Dillon Danis 17.4K posts
Something went wrong.
Something went wrong.